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Introduction: Previous in vitro and in vivo studies have demonstrated the protective properties of lipid 
endocannabinoids against amyloid-β (Aβ) induced neurotoxicity1,2. Lipid-derived endocannabinoid agonists 
such as 2-arachidonoylglycerol (2-AG) can exert their effects via both the extra- and intracellular cannabinoid 
receptor-1 (CB1)
3
. Pepcans are a group of haemoglobin derived peptide cannabinoids and are found throughout 
the CNS
3
. They are cell-impermeant and act on the extracellular CB1 receptor
3,4
 as agonists/antagonists. The 
pepcan RVD-hemopressin (RVD) is a CB1 receptor agonist
3
. The aim of this study was to determine whether 
RVD is protective against Aβ toxicity. 
Method: This study employed MTT cell viability assays to investigate the effects of the peptide CB1 agonist 
RVD and lipid CB1 agonist 2-AG plus the CB1 antagonist AM281 on Aβ 25-35 induced neurotoxicity in human 
neuroblastoma SH-SY5Y cells. Data was analyzed by one-way analysis of variance (ANOVA). 
Results: RVD (0.01-10µM) had no effect on 10µM Aβ 25-35 induced neurotoxicity in SH-SY5Y cells, whereas 
2-AG (0.02-10µM; P<0.05 vs Aβ 25-35 alone) promoted a concentration dependent inhibition (Figure 1A). The 
CB1 antagonist AM281 (10µM) had no effect on RVD (10µM) plus 10µM Aβ 25-35, however it abolished the 
protective effects of 2-AG (10µM; P<0.05 vs Aβ 25-35 alone) on 10µM Aβ 25-35 induced neurotoxicity 
(Figure 1B). 
 
 Figure 1. (A) Dose-response curves for RVD plus 10µM Aβ 25-35 and 2-AG plus 10µM Aβ 25-35 on MTT 
reduction in SH-SY5Y cells. (B) SH-SY5Y cells were exposed to 10µM Aβ 25-35 alone, or plus 10µM RVD 
alone or 10µM RVD and 10µM AM281 or 10µM 2-AG alone or 10µM 2-AG and 10µM AM281 and cell 
viability determined by MTT reduction. Results are mean ± SEM (n=8 for each data point); * = P< 0.05 vs Aβ 
25-35 alone; † = P<0.05 vs control; (one-way ANOVA). 
Conclusion: In conclusion, the peptide cannabinoid RVD is non-protective against Aβ 25-35 induced 
neurotoxicity in SH-SY5Y cells. Lipid based endocannabinoids, such as 2-AG, are protective against Aβ 25-35 
induced neurotoxicity
1. Our results support the suggestion that endocannabinoid neuroprotection against Aβ 
involves the intracellular CB1 receptor rather than the extracellular CB1 receptor
 5
. 
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